Home > Insider Trading > Filing (0001437749-23-016818)

Filing Details

Accession Number:: 0001437749-23-016818
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-06-06 20:41:51
Reporting Period:: 2022-12-22

Accepted Time:: 2023-06-06 20:41:51
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1494582	Boston Omaha Corp	BOC	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1475272	Boulderado Partners, Llc	292 Newbury St., Suite 333 Boston MA 02115		No	No	Yes	No
1527265	Boulderado Group, Llc	292 Newbury St., Suite 333 Boston MA 02115		No	No	Yes	No
1689124	Boulderado Capital, Llc	292 Newbury St., Suite 333 Boston MA 02115		No	No	Yes	No
1689425	Buffett Alexander Rozek	1601 Dodge Street Suite 3300 Omaha NE 68102	Co-Ceo, Co-President	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock, Par Value $0.001 Per Share	Disposition	2022-12-22	20,000	$0.00	1,056,203	No	4	J	Direct
Class A Common Stock, Par Value $0.001 Per Share	Disposition	2023-06-02	128,550	$0.00	939,253	No	4	J	Direct
Class A Common Stock, Par Value $0.001 Per Share	Disposition	2023-06-05	11,600	$19.74	927,653	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	J	Direct
No	4	J	Direct
No	4	S	Direct

Footnotes

On December 22, 2022, Boulderado Partners, LLC ("BP") redeemed interests of BP held by two foundations that are limited partners of BP in a specific A-3 zero fee series (collectively, the "Foundations"), in consideration for the distribution to each such Foundation of 10,000 shares of Class A common stock of the Issuer. Mr. Rozek is the President of each of the Foundations and may exercise voting and dispositive power over the Class A common stock held by the Foundations, but Mr. Rozek disclaims beneficial ownership over such shares and this report shall not be deemed an admission of beneficial ownership of these securities for Section 16 or for any other purposes.
Boulderado Capital, LLC ("BC"), Boulderado Group, LLC ("BG") and Mr. Rozek disclaim beneficial ownership except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission of beneficial ownership of these securities for Section 16 or for any other purposes.
Mr. Rozek serves as a director of the Issuer and is the Co-Chief Executive Officer and Co-President of the Issuer.
The reported shares are directly owned by BP, other than the shares distributed to the Foundations as described in footnote (1), to the Foundation and the Trusts as described in footnote (5) and as sold by the Medical Trust as described in footnote (6). BC is the managing member of BP. BG is the investment manager of BP. Mr. Rozek is the managing member of BP, BC and BG. BP, BC, BG and Mr. Rozek disclaim beneficial ownership except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission of beneficial ownership of these securities for Section 16 or for any other purposes.
On June 2, 2023, BP redeemed interests of BP held by one of the Foundations and three trusts that were limited partners of BP (collectively, the "Trusts"), including the Doris Buffett Medical Support Trust (the "Medical Trust"), in consideration of the distribution to one of the Foundations of 43,000 shares, and to the Trusts of 11,600 shares, 11,800 shares and 62,150 shares, respectively, of Class A common stock of the Issuer. Mr. Rozek is the President of each of the Foundations and is a trustee of each of the Trusts, and may exercise voting and dispositive power over the Class A common stock held by the Foundations and the Trusts. BP, BC, BG and Mr. Rozek disclaim beneficial ownership over such shares held by the Foundations and each of the Trusts, except that with regard to the Medical Trust, Mr. Rozek disclaims beneficial ownership except to the extent of his pecuniary interest therein.
The shares reported in Column 4 were sold by the Medical Trust.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.70 to $19.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.